BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bamhraz AA, Rahim KA, Faqeehi HY, Alanazi A. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study. Kidney Blood Press Res 2020;45:939-54. [PMID: 33238263 DOI: 10.1159/000510612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Alzabali S, Albatati S, Rahim K, Faqeehi H, Osman A, Bamhraz A, Saleh MA, Kari JA, Aloufi M, Eid L, Nasser H, Imam A, Alhammadi E, Alkandari O, Al Riyami M, Sethi S, Licht C, Alhasan KA, Alanazi A. A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome. Children 2022;9:1734. [DOI: 10.3390/children9111734] [Reference Citation Analysis]
2 de Souza RM, Correa BHM, Melo PHM, Pousa PA, de Mendonça TSC, Rodrigues LGC, Simões E Silva AC. The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review. Pediatr Nephrol 2022. [PMID: 35864223 DOI: 10.1007/s00467-022-05683-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Eculizumab. Reactions Weekly 2021;1842:163-163. [DOI: 10.1007/s40278-021-90899-0] [Reference Citation Analysis]